News Breaks |
|
|
| December 9, 2012 |
| 16:08 EDT |  | HALO, RHHBY | Roche filing triggers $4M milestone payment to Halozyme
Halozyme Therapeutics (HALO) announced that Roche (RHHBY) has submitted a line extension application to the European Medicines Agency for a subcutaneous, SC, formulation of MabTheraŽ (rituxumab). The filing of the application triggered a $4M milestone payment to Halozyme under the License and Collaboration Agreement between Halozyme and Roche. |
|
|
News For HALO;RHHBY From The Last 14 Days Check below for free stories on HALO;RHHBY the last two weeks. |
|
|
| May 16, 2013 |
| 08:42 EDT |  | HALO | Halozyme data favorable, says JMP Securities
JMP Securities was highly encouraged by data from a Phase I trial of Halozyme's PEGPH20 in pancreatic cancer, as the drug generated response rates that were significantly higher than competing drugs, according to the firm. JMP Securities raised its target on Halozyme to $12 from $10 and reiterates an Outperform rating on the shares. |
|
| May 15, 2013 |
| 18:07 EDT | | HALO | Halozyme to present new PEGPH20 phase 1b trial data
Halozyme Therapeutics announced that clinical data from a phase 1b trial of PEGPH20, an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology annual meeting. In this phase 1b study, 28 stage IV pancreatic ductal adenocarcinoma patients were treated with PEGPH20 in combination with gemcitabine. The overall response rate was 42%as assessed by independent review at therapeutic dose levels of PEGPH20. Treatment was generally well tolerated and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. There was no evidence of new observed toxicity. Based on the magnitude of response and safety observed in the Phase 1b study, Halozyme announced in April the initiation of a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer. |
|
| 15:59 EDT |  | RHHBY | Roche exploring sale of blood glucose meters unit, Reuters says
 Subscribe for More Information |
|
| 12:13 EDT |  | RHHBY | Roche management to meet with Jefferies
Meeting to be held in London on May 17 hosted by Jefferies. |
|
| 11:38 EDT | | RHHBY | Roche says FDA approves Tarceva tablets for specific lung cancer situation
Subscribe for More Information |
|
| 10:13 EDT |  | HALO | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| May 14, 2013 |
| 16:55 EDT | | RHHBY | FDA approves Roche's cobas EGFR mutation test with Tarceva
Subscribe for More Information |
|
| 16:08 EDT | | HALO | Halozyme initiated with an Overweight at Piper Jaffray
Subscribe for More Information |
|
| May 13, 2013 |
| 08:55 EDT | | RHHBY | Biosimiliar drug bill to be taken up in Senate, LA Times reports
Subscribe for More Information |
|
| 07:30 EDT | | RHHBY | TechConnect to host a summit
2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. |
| |
| May 10, 2013 |
| 15:59 EDT | | RHHBY | Roche spokesman reiterates that Illumina is "off the table," Bloomberg reports
Subscribe for More Information |
|
| 11:48 EDT | | RHHBY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| May 8, 2013 |
| 16:32 EDT |  | HALO | Halozyme reports Q1 EPS (17c), consensus (15c)
Subscribe for More Information |
|
| May 6, 2013 |
| 07:18 EDT | | RHHBY | American Congress of Obstetrics and Gynecology to hold annual meeting
Subscribe for More Information |
|
|
|
|
|
